All Videos

This patient hasn't reached Hurley Stage 3, but her quality of life already has. The panel makes the case for escalating therapy well before anatomic damage sets in.

A five-year history of 'ingrown hairs' turns out to be HS. The panel explores why primary care so often misses this diagnosis, and how to rebuild trust once it's finally named.

Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.

Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.

Dr. Chandra details the CPOST trial, a randomized phase 3 study in which 415 patients received either adjuvant cemiplimab for one year or placebo.

This episode, "Inside the Risankizumab and PsA Risk Study: Claims Data on Targeted Immunomodulator Therapies," examines the study design and the numbers behind it.

Learn how dermatologists can pinpoint causes of scarring vs nonscarring hair loss, avoid biotin pitfalls, and choose personalized treatments early.

A 48-year-old man with chronic plaque psoriasis develops new intertriginous involvement unresponsive to prior topical regimens. Dr. Bhutani-Jacques outlines how lesion location and treatment history inform selection of a non-steroidal topical agent.

Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.

Aaron Farberg, MD, outlines common triggers of generalized pustular psoriasis flares and the role of IL-36 targeted therapy.

Aaron Farberg, MD, reviews the diagnostic challenges of generalized pustular psoriasis and its common mimics across care settings.

Eileen Cheever, PA, discussed family hesitancy toward systemic pediatric psoriasis treatment and age-related treatment gaps in dermatology.

Aaron Farberg, MD, discusses why generalized pustular psoriasis warrants its own awareness day and how it differs immunologically from plaque psoriasis.

Victoria Garcia-Albea, NP, discussed the learning curve dermatology NP fellows experience and the need for greater dermatology education for APPs.

Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.

Jerry Shapiro, MD, explains VDPHL01's cardiac safety profile and patient-reported outcomes in a phase 2 trial for female pattern hair loss.

New IL-17 inhibitors are changing first-line choices for adolescent and adult HS alike. The panel weighs efficacy benchmarks against follow-up strategy and comorbidity screening.

Parents often hear 'biologic' and imagine the worst. The panel explains how they build trust, set expectations, and time that first injection.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses TAMES-02 phase 2 trial enrollment and a new blister burden end point in EBS.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Martina Porter, MD, highlights phase 3 data showing povorcitinib boosts hidradenitis suppurativa responses by week 3 and sustains gains to 54 weeks in refractory patients.

With Mohs surgery complete, three stages to clear a defect greater than four centimeters extending to the periosteum, Dr. Patel details the pathology: a poorly differentiated tumor, 5.7 millimeters thick, with multifocal small-caliber perineural invasion above the clinically significant threshold.

In "Can Psoriasis Treatment Prevent PsA? Biologics, Phototherapy, and Other Treatments," Dr. Strober takes up whether some psoriasis treatments do more than clear skin.

Dr. Patel introduces the second case: a 72-year-old man with a rapidly enlarging lesion on the left forehead, now just over three centimeters, ulcerated, and sitting above the left eyebrow.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.

Leon Kircik, MD, discusses the allosteric binding mechanism and safety profile data of zasocitinib in hard-to-treat psoriasis presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Jerry Shapiro, MD, discusses rapid hair growth and safety findings for oral minoxidil, VDPHL01, in female pattern hair loss.

Isoclear regimen combines topical isotretinoin with stage-specific ingredients from active treatment through long-term maintenance

Leon Kircik, MD, outlines phase 3 zasocitinib data on palmoplantar psoriasis skin clearance presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Aaron Farberg, MD, discusses how localized isotretinoin delivery may affect treatment burden, tolerability, and adherence.